150 related articles for article (PubMed ID: 38402449)
1. Enfortumab vedotin prolongs overall survival in metastatic urothelial carcinoma following pembrolizumab therapy in real-world data.
Uemura K; Ito H; Jikuya R; Kondo T; Tatenuma T; Kawahara T; Ito Y; Komeya M; Muraoka K; Hasumi H; Uemura H; Makiyama K
Int J Urol; 2024 Feb; ():. PubMed ID: 38402449
[TBL] [Abstract][Full Text] [Related]
2. Durable Response to Enfortumab Vedotin Compared to Re-challenging Chemotherapy in Metastatic Urothelial Carcinoma After Checkpoint Inhibitors.
Uchimoto T; Tsuchida S; Komura K; Fukuokaya W; Adachi T; Hirasawa Y; Hashimoto T; Yoshizawa A; Saruta M; Hashimoto M; Higashio T; Matsuda T; Nishimura K; Tsujino T; Nakamura K; Fukushima T; Nishio K; Yamamoto S; Iwatani K; Urabe F; Mori K; Yanagisawa T; Tsuduki S; Takahara K; Inamoto T; Miki J; Fujita K; Kimura T; Ohno Y; Shiroki R; Uemura H; Azuma H
Target Oncol; 2024 May; 19(3):401-410. PubMed ID: 38546942
[TBL] [Abstract][Full Text] [Related]
3. Comparison of the efficacy of enfortumab vedotin between patients with metastatic urothelial carcinoma who were treated with avelumab or pembrolizumab: real-world data from a multi-institutional study in Japan.
Hirasawa Y; Adachi T; Hashimoto T; Fukuokaya W; Koike Y; Yata Y; Komura K; Uchimoto T; Tsujino T; Nishimura K; Takahara K; Saruta M; Fujita K; Hashimoto M; Uemura H; Shiroki R; Azuma T; Kimura T; Ohno Y
J Cancer Res Clin Oncol; 2024 Apr; 150(4):182. PubMed ID: 38592548
[TBL] [Abstract][Full Text] [Related]
4. Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer.
Powles T; Valderrama BP; Gupta S; Bedke J; Kikuchi E; Hoffman-Censits J; Iyer G; Vulsteke C; Park SH; Shin SJ; Castellano D; Fornarini G; Li JR; Gümüş M; Mar N; Loriot Y; Fléchon A; Duran I; Drakaki A; Narayanan S; Yu X; Gorla S; Homet Moreno B; van der Heijden MS;
N Engl J Med; 2024 Mar; 390(10):875-888. PubMed ID: 38446675
[TBL] [Abstract][Full Text] [Related]
5. Enfortumab vedotin after PD-1 or PD-L1 inhibitors in cisplatin-ineligible patients with advanced urothelial carcinoma (EV‑201): a multicentre, single-arm, phase 2 trial.
Yu EY; Petrylak DP; O'Donnell PH; Lee JL; van der Heijden MS; Loriot Y; Stein MN; Necchi A; Kojima T; Harrison MR; Hoon Park S; Quinn DI; Heath EI; Rosenberg JE; Steinberg J; Liang SY; Trowbridge J; Campbell M; McGregor B; Balar AV
Lancet Oncol; 2021 Jun; 22(6):872-882. PubMed ID: 33991512
[TBL] [Abstract][Full Text] [Related]
6. Administration of Enfortumab Vedotin after Immune-Checkpoint Inhibitor and the Prognosis in Japanese Metastatic Urothelial Carcinoma: A Large Database Study on Enfortumab Vedotin in Metastatic Urothelial Carcinoma.
Kawahara T; Hasizume A; Uemura K; Yamaguchi K; Ito H; Takeshima T; Hasumi H; Teranishi JI; Ousaka K; Makiyama K; Uemura H
Cancers (Basel); 2023 Aug; 15(17):. PubMed ID: 37686503
[TBL] [Abstract][Full Text] [Related]
7. Outcomes of metastatic urothelial carcinoma following discontinuation of enfortumab-vedotin.
Curran C; Adib E; Kazakova V; Grivas P; Diamantopoulos LN; Alva AS; Su C; Jain RK; Tandon A; Necchi A; Marandino L; Plastini TM; Merchan JR; Sonpavde G
Clin Genitourin Cancer; 2022 Feb; 20(1):11-16. PubMed ID: 34503934
[TBL] [Abstract][Full Text] [Related]
8. Enfortumab Vedotin in Metastatic Urothelial Carcinoma: Survival and Safety in a European Multicenter Real-world Patient Cohort.
Zschäbitz S; Biernath N; Hilser T; Höllein A; Zengerling F; Cascucelli J; Paffenholz P; Seidl D; Lutz C; Schlack K; Kingreen D; Klümper N; Ivanyi P; von Amsberg G; Heers H; Roghmann F; Tauber RL; Cathomas R; Hofer L; Niegisch G; Klee M; Ehrenberg R; Hassler A; Hadaschik BA; Grünwald V; Darr C
Eur Urol Open Sci; 2023 Jul; 53():31-37. PubMed ID: 37441344
[TBL] [Abstract][Full Text] [Related]
9. Enfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma.
Powles T; Rosenberg JE; Sonpavde GP; Loriot Y; Durán I; Lee JL; Matsubara N; Vulsteke C; Castellano D; Wu C; Campbell M; Matsangou M; Petrylak DP
N Engl J Med; 2021 Mar; 384(12):1125-1135. PubMed ID: 33577729
[TBL] [Abstract][Full Text] [Related]
10. Enfortumab vedotin and pembrolizumab as monotherapies and combination treatment in locally advanced or metastatic urothelial carcinoma: A narrative review.
Bantounou MA; Plascevic J; MacDonald L; Wong MC; O'Connell N; Galley HF
Curr Urol; 2023 Dec; 17(4):271-279. PubMed ID: 37994340
[TBL] [Abstract][Full Text] [Related]
11. C-Reactive Protein-Albumin Ratio Predicts Objective Response to Enfortumab Vedotin in Metastatic Urothelial Carcinoma.
Uchimoto T; Matsuda T; Komura K; Fukuokaya W; Adachi T; Hirasawa Y; Hashimoto T; Yoshizawa A; Saruta M; Hashimoto M; Higashio T; Tsuchida S; Nishimura K; Tsujino T; Nakamura K; Fukushima T; Nishio K; Yamamoto S; Iwatani K; Urabe F; Mori K; Yanagisawa T; Tsuduki S; Takahara K; Inamoto T; Miki J; Fujita K; Kimura T; Ohno Y; Shiroki R; Uemura H; Azuma H
Target Oncol; 2024 May; ():. PubMed ID: 38807017
[TBL] [Abstract][Full Text] [Related]
12. Enfortumab vedotin versus platinum rechallenge in post-platinum, post-pembrolizumab advanced urothelial carcinoma: A multicenter propensity score-matched study.
Taguchi S; Kawai T; Ambe Y; Kishitani K; Sugimoto K; Miyakawa J; Nakamura Y; Noda M; Kaneko T; Kamei J; Obinata D; Yamaguchi K; Kakutani S; Furuya Y; Sato Y; Uemura Y; Akiyama Y; Yamada Y; Sato Y; Yamada D; Enomoto Y; Nishimatsu H; Fujimura T; Fukuhara H; Nakagawa T; Takahashi S; Kume H
Int J Urol; 2023 Dec; 30(12):1180-1186. PubMed ID: 37740409
[TBL] [Abstract][Full Text] [Related]
13. Enfortumab vedotin in metastatic urothelial carcinoma: the solution EVentually?
Maiorano BA; Catalano M; Maiello E; Roviello G
Front Oncol; 2023; 13():1254906. PubMed ID: 37781180
[TBL] [Abstract][Full Text] [Related]
14. Health-related Quality of Life of Patients with Locally Advanced or Metastatic Urothelial Cancer Treated with Enfortumab Vedotin after Platinum and PD-1/PD-L1 Inhibitor Therapy: Results from Cohort 1 of the Phase 2 EV-201 Clinical Trial.
McGregor B; O'Donnell PH; Balar A; Petrylak D; Rosenberg J; Yu EY; Quinn DI; Heath EI; Campbell M; Hepp Z; McKay C; Steinberg J; Regnault A; Mazerolle F; Galsky MD
Eur Urol; 2022 May; 81(5):515-522. PubMed ID: 35168844
[TBL] [Abstract][Full Text] [Related]
15. Clinical practice pattern in patients with advanced urothelial cancer who had progressed on pembrolizumab in the pre-enfortumab vedotin era.
Kita Y; Ito K; Sano T; Hashimoto K; Mochizuki T; Shiraishi Y; Araki H; Fujiwara M; Kanamaru S; Takahashi T; Hishiki K; Okada T; Ogawa K; Ito M; Kojima T; Nishiyama N; Matsui Y; Nishiyama H; Kitamura H; Kobayashi T
Int J Urol; 2022 Jul; 29(7):647-655. PubMed ID: 35304776
[TBL] [Abstract][Full Text] [Related]
16. Enfortumab vedotin following platinum-based chemotherapy and immune checkpoint inhibitors for advanced urothelial carcinoma: response, survival and safety analysis from a multicentre real-world Japanese cohort.
Miyake M; Nishimura N; Oda Y; Miyamoto T; Ohmori C; Takamatsu N; Itami Y; Tachibana A; Matsumoto Y; Kiba K; Tomioka A; Yamamoto H; Okajima E; Masaomi K; Sakamoto K; Tomizawa M; Shimizu T; Ohnishi K; Hori S; Morizawa Y; Gotoh D; Nakai Y; Torimoto K; Tanaka N; Fujimoto K;
Jpn J Clin Oncol; 2024 Mar; 54(3):329-338. PubMed ID: 38061911
[TBL] [Abstract][Full Text] [Related]
17. EV-301 long-term outcomes: 24-month findings from the phase III trial of enfortumab vedotin versus chemotherapy in patients with previously treated advanced urothelial carcinoma.
Rosenberg JE; Powles T; Sonpavde GP; Loriot Y; Duran I; Lee JL; Matsubara N; Vulsteke C; Castellano D; Mamtani R; Wu C; Matsangou M; Campbell M; Petrylak DP
Ann Oncol; 2023 Nov; 34(11):1047-1054. PubMed ID: 37678672
[TBL] [Abstract][Full Text] [Related]
18. EV-101: A Phase I Study of Single-Agent Enfortumab Vedotin in Patients With Nectin-4-Positive Solid Tumors, Including Metastatic Urothelial Carcinoma.
Rosenberg J; Sridhar SS; Zhang J; Smith D; Ruether D; Flaig TW; Baranda J; Lang J; Plimack ER; Sangha R; Heath EI; Merchan J; Quinn DI; Srinivas S; Milowsky M; Wu C; Gartner EM; Zuo P; Melhem-Bertrandt A; Petrylak DP
J Clin Oncol; 2020 Apr; 38(10):1041-1049. PubMed ID: 32031899
[TBL] [Abstract][Full Text] [Related]
19. Pivotal Trial of Enfortumab Vedotin in Urothelial Carcinoma After Platinum and Anti-Programmed Death 1/Programmed Death Ligand 1 Therapy.
Rosenberg JE; O'Donnell PH; Balar AV; McGregor BA; Heath EI; Yu EY; Galsky MD; Hahn NM; Gartner EM; Pinelli JM; Liang SY; Melhem-Bertrandt A; Petrylak DP
J Clin Oncol; 2019 Oct; 37(29):2592-2600. PubMed ID: 31356140
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of enfortumab vedotin in advanced urothelial cancer: Analysis from the Urothelial Cancer Network to Investigate Therapeutic Experiences (UNITE) study.
Koshkin VS; Henderson N; James M; Natesan D; Freeman D; Nizam A; Su CT; Khaki AR; Osterman CK; Glover MJ; Chiang R; Makrakis D; Talukder R; Lemke E; Olsen TA; Jain J; Jang A; Ali A; Jindal T; Chou J; Friedlander TW; Hoimes C; Basu A; Zakharia Y; Barata PC; Bilen MA; Emamekhoo H; Davis NB; Shah SA; Milowsky MI; Gupta S; Campbell MT; Grivas P; Sonpavde GP; Kilari D; Alva AS
Cancer; 2022 Mar; 128(6):1194-1205. PubMed ID: 34882781
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
